26KIT
Medtronic
In May 2023, Medtronic announced
that it had entered into a set of
agreements to acquire insulin
delivery technology developer
EOFlow. South Korea-based EOFlow
develops the EOPatch - a tubeless,
wearable and fully disposable insulin
delivery device. Medtronic plans
to integrate its new insulin dosing
algorithm, which is used in the 780G
pump, with EOFlow's pump and is
offering to buy all outstanding shares
of EOFlow,
EOFlow's technology currently
is authorized in Europe, South
Korea, Indonesia and the United
Arab Emirates, with a smartphone
application that allows users to
monitor and control the patch
directly from their phone. EOFlow's
founder Jesse Kim said that the
transaction would accelerate the
company's next phase of growth,
"With a global footprint in over
100 countries, ability to scale up
manufacturing quickly, and advanced
software and sensor capabilities,
Medtronic is the ideal strategic
partner for EOFlow."
We have previously covered
EOFLow as it is part of the French
Diabeloop project.
Novo Nordisk
In early June 2023, Novo Nordisk
announced it had entered into
exclusive negotiations to acquire a
controlling stake in French Biocorp,
to be followed by a tender offer on all
remaining shares.
Biocorp has specialised in
the design, development and
manufacturing of delivery systems
and innovative medical devices,
including Mallya, a Bluetoothenabled
smart add-on device for pen
injectors. Since 2021 the companies
have been collaborating on the
development and commercialisation
of a Mallya add-on device for the
Novo Nordisk FlexTouch pen used
by people with diabetes, and during
2022 and 2023 this engagement has
been expanded to the development
of versions of the Mallya device for
other therapy areas.
devices, such as the SmartPilot for
YpsoMate, are pre-integrated in
the platform.
Ulrike Bauer, Chief Business
Officer Delivery Systems for
Ypsomed explained, "The new
platform will enable our Pharma and
Biotech customers to rapidly launch
integrated device and digital health
solutions that will further improve
therapy outcomes and quality of life
for their patients."
Digital health solutions play
an increasingly important role in
how well patients with acute and
chronic diseases manage their
therapy. The new product offering
will be marketed through Ypsomed
and will be offered to customers in
collaboration with S3 Connected
Health for customization to serve
their specific use cases and brand.
The new platform offering
includes a patient application, a
clinical system, a Patient Support
Portal and analytical dashboard with
real-time access to anonymized
data. Alongside pre-integration
of Ypsomed's device portfolio, the
platform provides a range of features
around self-injection, incorporates
behavioral science mechanisms to
ensure high levels of engagement,
and personalization of the application
to users' needs.
www.ypsomed-uk.com
Following the acquisition, Novo
Nordisk would aim to preserve the
agility and entrepreneurial spirit of
BIOCORP, while investing further
in the organization with the goal of
delivering cutting edge devices and
delivery solutions to improve care for
people across the globe living with
serious chronic diseases.
Ypsomed
Ypsomed is to expand its offering
of digital health solutions in
partnership with S3 Connected
Health. Headquartered in Dublin,
S3 Connected Health is a specialist
digital health partner for life science
companies. Together the companies
intend to create an extendable
platform to create specific solutions
to provide patients with support and
guidance throughout their therapy.
Ypsomed's connected injection